1. Home
  2. TTD vs BLCO Comparison

TTD vs BLCO Comparison

Compare TTD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Trade Desk Inc.

TTD

The Trade Desk Inc.

HOLD

Current Price

$12.69

Market Cap

6.5B

Sector

Technology

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$17.05

Market Cap

6.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTD
BLCO
Founded
2009
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Ophthalmic Goods
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.1B
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
TTD
BLCO
Price
$12.69
$17.05
Analyst Decision
Buy
Buy
Analyst Count
34
11
Target Price
$46.22
$18.45
AVG Volume (30 Days)
16.4M
376.0K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
15.38
N/A
EPS
0.22
N/A
Revenue
$2,896,284,000.00
$5,101,000,000.00
Revenue This Year
$13.94
$8.65
Revenue Next Year
$12.61
$5.59
P/E Ratio
$60.16
N/A
Revenue Growth
18.47
6.47
52 Week Low
$12.83
$13.77
52 Week High
$55.10
$18.92

Technical Indicators

Market Signals
Indicator
TTD
BLCO
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
TTD
BLCO

About TTD The Trade Desk Inc.

The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. The firm's platform is referred to as a DSP in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising, sometimes referred to as a "take rate."

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: